» Articles » PMID: 35124887

ChREBP-driven DNL and PNPLA3 Expression Induced by Liquid Fructose Are Essential in the Production of Fatty Liver and Hypertriglyceridemia in a High-Fat Diet-Fed Rat Model

Overview
Date 2022 Feb 6
PMID 35124887
Authors
Affiliations
Soon will be listed here.
Abstract

Scope: The aim of this study is to delineate the contribution of dietary saturated fatty acids (FA) versus liquid fructose to fatty liver and hypertriglyceridemia.

Methods And Results: Three groups of female rats are maintained for 3 months in standard chow (CT); High-fat diet (46.9% of fat-derived calories, rich in palmitic and stearic FA, HFD); and HFD with 10% w/v fructose in drinking water (HFHFr). Zoometric parameters, plasma biochemistry, and liver Oil-Red O (ORO) staining, lipidomics, and expression of proteins involved in FA metabolism are analyzed. Both diets increase ingested calories without modifying body weight. Only the HFHFr diet increases liver triglycerides (x11.0), with hypertriglyceridemia (x1.7) and reduces FA β-oxidation (x0.7), and increases liver FA markers of DNL (de novo lipogenesis). Whereas HFD livers show a high content of ceramides, HFHFr samples show unchanged ceramides, and an increase in diacylglycerols. Only the HFHFr diet leads to a marked increase in the expression of enzymes involved in DNL and triglyceride metabolism, such as carbohydrate response element binding protein β (ChREBPβ, x3.2), a transcription factor that regulates DNL, and patatin-like phospholipase domain-containing 3 (PNPLA3, x2.6), a lipase that mobilizes stored triglycerides for VLDL secretion.

Conclusion: The addition of liquid-fructose to dietary FA is determinant in liver steatosis and hypertriglyceridemia production, through increased DNL and PNPLA3 expression, and reduced FA catabolism.

Citing Articles

Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2.

Buttari B, Tramutola A, Rojo A, Chondrogianni N, Saha S, Berry A Biomolecules. 2025; 15(1).

PMID: 39858508 PMC: 11764413. DOI: 10.3390/biom15010113.


Current strategies for nonalcoholic fatty liver disease treatment (Review).

Sun J, Jin X, Li Y Int J Mol Med. 2024; 54(4).

PMID: 39129305 PMC: 11335354. DOI: 10.3892/ijmm.2024.5412.


Sex Differences Affect the NRF2 Signaling Pathway in the Early Phase of Liver Steatosis: A High-Fat-Diet-Fed Rat Model Supplemented with Liquid Fructose.

Di Veroli B, Bentanachs R, Roglans N, Alegret M, Giona L, Profumo E Cells. 2024; 13(15.

PMID: 39120278 PMC: 11312139. DOI: 10.3390/cells13151247.


Activation of skeletal carbohydrate-response element binding protein (ChREBP)-mediated de novo lipogenesis increases intramuscular fat content in chickens.

Wang P, Xiao H, Wu T, Fu Q, Song X, Zhao Y Anim Nutr. 2024; 18:107-118.

PMID: 39091296 PMC: 11292260. DOI: 10.1016/j.aninu.2024.04.006.


Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective.

Fu Y, Wang Z, Qin H Metabolites. 2024; 14(4).

PMID: 38668346 PMC: 11052500. DOI: 10.3390/metabo14040218.


References
1.
Zammit V . Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia. Biochem J. 2013; 451(1):1-12. DOI: 10.1042/BJ20121689. View

2.
Zhou H, Urso C, Jadeja V . Saturated Fatty Acids in Obesity-Associated Inflammation. J Inflamm Res. 2020; 13:1-14. PMC: 6954080. DOI: 10.2147/JIR.S229691. View

3.
Wang S, Chen Z, Lam V, Han J, Hassler J, Finck B . IRE1α-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis. Cell Metab. 2012; 16(4):473-86. PMC: 3569089. DOI: 10.1016/j.cmet.2012.09.003. View

4.
Vila L, Roglans N, Perna V, Sanchez R, Vazquez-Carrera M, Alegret M . Liver AMP/ATP ratio and fructokinase expression are related to gender differences in AMPK activity and glucose intolerance in rats ingesting liquid fructose. J Nutr Biochem. 2010; 22(8):741-51. DOI: 10.1016/j.jnutbio.2010.06.005. View

5.
Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G . PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab. 2006; 292(2):E421-34. PMC: 2665003. DOI: 10.1152/ajpendo.00157.2006. View